TY - JOUR
T1 - Ropinirole in the treatment of early Parkinson's disease
T2 - A 6-month interim report of a 5-year levodopa-controlled study
AU - Rascol, Olivier
AU - Brooks, David J.
AU - Brunt, Ehrout R.
AU - Korczyn, Amos D.
AU - Poewe, Warner H.
AU - Stocchi, Fabrizzio
PY - 1998
Y1 - 1998
N2 - The efficacies of ropinirole and levodopa were compared after 6 months of treatment in a planned interim analysis of a 5-year, double-blind, randomized, multicenter study of patients with early Parkinson's disease requiring dopaminergic therapy. The percentage of improvement in the Unified Parkinson's Disease Rating Scale total motor examination score was significantly higher for levodopa (44%) than for ropinirole (32%). The proportion of 'responders' (Unified Parkinson's Disease Rating Scale improvement of at least 30%) did not differ between groups (levodopa, 58%; ropinirole, 48%). There was no difference between the groups for improvement on the Clinical Global impression scale in patients with Hoehn and Yahr stages I, I.5, or II, but a significantly higher proportion of patients with Hoehn and Yahr stages II.5 or III showed Clinical Global Impression score improvement with levodopa. Emergent adverse events occurred in 84% of patients in both treatment groups, the principal symptom in each group being nausea. The incidence of serious adverse events was low (8% for ropinirole, 9% for levodopa). The results suggest that ropinirole and levodopa are equally effective in less severe Parkinson's disease; in more advanced Parkinson's disease, levodopa is superior.
AB - The efficacies of ropinirole and levodopa were compared after 6 months of treatment in a planned interim analysis of a 5-year, double-blind, randomized, multicenter study of patients with early Parkinson's disease requiring dopaminergic therapy. The percentage of improvement in the Unified Parkinson's Disease Rating Scale total motor examination score was significantly higher for levodopa (44%) than for ropinirole (32%). The proportion of 'responders' (Unified Parkinson's Disease Rating Scale improvement of at least 30%) did not differ between groups (levodopa, 58%; ropinirole, 48%). There was no difference between the groups for improvement on the Clinical Global impression scale in patients with Hoehn and Yahr stages I, I.5, or II, but a significantly higher proportion of patients with Hoehn and Yahr stages II.5 or III showed Clinical Global Impression score improvement with levodopa. Emergent adverse events occurred in 84% of patients in both treatment groups, the principal symptom in each group being nausea. The incidence of serious adverse events was low (8% for ropinirole, 9% for levodopa). The results suggest that ropinirole and levodopa are equally effective in less severe Parkinson's disease; in more advanced Parkinson's disease, levodopa is superior.
KW - Dopamine agonist
KW - Double-blind, controlled study
KW - Early Parkinson's disease
KW - Levodopa
KW - Ropinirole
UR - http://www.scopus.com/inward/record.url?scp=0031965147&partnerID=8YFLogxK
U2 - 10.1002/mds.870130111
DO - 10.1002/mds.870130111
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 9452324
AN - SCOPUS:0031965147
VL - 13
SP - 39
EP - 45
JO - Movement Disorders
JF - Movement Disorders
SN - 0885-3185
IS - 1
ER -